Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights

During the last three months, 8 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	8	0	0	0	0
Last 30D	1	0	0	0	0
1M Ago	2	0	0	0	0
2M Ago	3	0	0	0	0
3M Ago	2	0	0	0	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.0, a high estimate of $10.00, and a low estimate of $10.00. No alteration is observed as the current average remains at the previous average price target.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Lexicon Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lexicon Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lexicon Pharmaceuticals compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Lexicon Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lexicon Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Lexicon Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Key Indicators: Lexicon Pharmaceuticals's Financial Health

Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Revenue Growth: Lexicon Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 419.56%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Lexicon Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3244.02%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -20.21%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Lexicon Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.52%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Lexicon Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.